ClinConnect ClinConnect Logo
Search / Trial NCT01283724

Visanne Study to Assess Safety in Adolescents

Launched by BAYER · Jan 25, 2011

Trial Information

Current as of May 22, 2025

Completed

Keywords

Endometriosis Dexa Adolescent Safety Efficacy Post Menarche

ClinConnect Summary

No description provided

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • Female adolescents after menarche (12 - less than 18 years of age) at screening. For Finland: Adolescents aged 12 - 14 years old who present with clinical features of endometriosis will only be enrolled into the study if their diagnosis of endometriosis has been confirmed by laparoscopy.
  • * Dysmenorrhea of at least moderate intensity, with or without chronic pelvic pain, for at least 2 cycles in the previous 4 months and one of the following conditions:
  • Clinically suspected endometriosis based on the presence of pelvic pain incompletely relieved by non steroidal anti-inflammatory drugs and/or oral contraceptives
  • Any abdominal pain associated with ultrasound findings suggestive of endometriosis (abdominal, vaginal or rectal; only after additional specific consent and assent)
  • Failure of surgical treatment for endometriosis (with cyclic or chronic pelvic pain of at least 4 months duration postsurgery)
  • Threshold for endometriosis-associated pelvic pain (EAPP) score: at least 30 on a 100 units visual analog scale retrospectively evaluated at screening for the last 4 weeks
  • Exclusion Criteria:
  • Absence of endometriosis at laparoscopy
  • Previous application of hormonal agents including oral contraceptives within 2 months, progestins, danazol within 3 months, and Gonadotropin Releasing Hormone (GnRH) agonists within 6 months prior to start of treatment
  • Chronic pelvic pain that might be related to genitourinary disease or to chronic or recurrent gastrointestinal disease, including irritable bowel syndrome (defined as a disease characterized by pain relieved by defecation and irregular defecation patterns lasting at least 3 months)
  • Clinically established need for primary surgical treatment of endometriosis

About Bayer

Bayer is a global healthcare and life sciences company dedicated to advancing health and well-being through innovative research and development. With a strong commitment to improving patient outcomes, Bayer conducts clinical trials across various therapeutic areas, including oncology, cardiology, and women's health. The company leverages cutting-edge science and technology to develop breakthrough therapies, while adhering to the highest standards of ethical practices and regulatory compliance. Through collaboration with healthcare professionals and research institutions, Bayer aims to bring transformative solutions to the market, ultimately enhancing the quality of life for patients worldwide.

Locations

Innsbruck, , Austria

Valencia, , Spain

Berlin, , Germany

Hamburg, , Germany

Wien, , Austria

Münster, Nordrhein Westfalen, Germany

Linz, Oberösterreich, Austria

Erlangen, Bayern, Germany

Paris, , France

Rouen, , France

Sevilla, , Spain

St. Pölten, Niederösterreich, Austria

Le Kremlin Bicetre, , France

Vigo, , Spain

Helsinki, , Finland

Turku, , Finland

Espoo, , Finland

Praha 2, , Czech Republic

Lübeck, Schleswig Holstein, Germany

Brno, , Czech Republic

Oldenburg, Niedersachsen, Germany

Angers Cedex 01, , France

Westerstede, , Germany

Benidorm, Alicante, Spain

Ceske Budejovice, , Czech Republic

Pisek, , Czech Republic

Praha, , Czech Republic

Graz, Steiermark, Austria

Patients applied

0 patients applied

Trial Officials

Bayer Study Director

Study Director

Bayer

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials